Botanix Pharmaceuticals Limited
BXPHF
$0.25
$0.000.00%
Weiss Ratings | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Very Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Good | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -6.92 | |||
Price History | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 13.64% | |||
30-Day Total Return | -13.79% | |||
60-Day Total Return | -21.88% | |||
90-Day Total Return | 4.17% | |||
Year to Date Total Return | 0.00% | |||
1-Year Total Return | 108.86% | |||
2-Year Total Return | 316.67% | |||
3-Year Total Return | 357.88% | |||
5-Year Total Return | 525.00% | |||
52-Week High % Change | -50.00% | |||
52-Week Low % Change | 2,841.18% | |||
Price | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $0.50 | |||
52-Week Low Price | $0.01 | |||
52-Week Low Price (Date) | Apr 19, 2024 | |||
52-Week High Price (Date) | Jun 21, 2024 | |||
Valuation | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 528.77M | |||
Enterprise Value | 498.81M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.01 | |||
Earnings Per Share Growth | 208.33% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 357.14 | |||
Price/Book (Q) | 7.94 | |||
Enterprise Value/Revenue (TTM) | 366.70 | |||
Price | $0.25 | |||
Enterprise Value/EBITDA (TTM) | -19.28 | |||
Enterprise Value/EBIT | -18.72 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 1.82B | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 61 8 6555 2945 | |||
Address | 41 – 47 Colin Street West Perth, WA 6005 | |||
Website | www.botanixpharma.com | |||
Country | Australia | |||
Year Founded | 1984 | |||
Profitability | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -1,958.84% | |||
Profit Margin | -1,903.27% | |||
Management Effectiveness | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -35.49% | |||
Return on Equity | -- | |||
Income Statement | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 1.36M | |||
Total Revenue (TTM) | 1.36M | |||
Revenue Per Share | $0.00 | |||
Gross Profit (TTM) | -1.20M | |||
EBITDA (TTM) | -25.92M | |||
EBIT (TTM) | -26.70M | |||
Net Income (TTM) | -25.94M | |||
Net Income Avl. to Common (TTM) | -25.94M | |||
Total Revenue Growth (Q YOY) | -0.16% | |||
Earnings Growth (Q YOY) | -464.91% | |||
EPS Diluted (TTM) | -0.01 | |||
EPS Diluted Growth (Q YOY) | -358.33% | |||
Balance Sheet | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 29.98M | |||
Cash Per Share (Q) | $0.02 | |||
Total Current Assets (Q) | 41.95M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 57.24M | |||
Current Ratio (Q) | 10.633 | |||
Book Value Per Share (Q) | $0.03 | |||
Total Assets (Q) | 61.54M | |||
Total Current Liabilities (Q) | 3.95M | |||
Total Debt (Q) | 536.10K | |||
Total Liabilities (Q) | 4.31M | |||
Total Common Equity (Q) | 57.24M | |||
Cash Flow | BXPHF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -2.69M | |||
Cash from Financing (TTM) | 45.25M | |||
Net Change in Cash (TTM) | 19.75M | |||
Levered Free Cash Flow (TTM) | -17.82M | |||
Cash from Operations (TTM) | -23.07M | |||